NTLA Intellia Therapeutics Inc

Price (delayed)

$26.46

Market cap

$2.55B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.36

Enterprise value

$2.49B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The gross profit has grown by 45% from the previous quarter
Intellia Therapeutics's revenue has increased by 45% QoQ
The company's quick ratio fell by 7% YoY but it rose by 2.7% QoQ
The net income has contracted by 13% YoY
Intellia Therapeutics's equity has decreased by 13% YoY

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
96.48M
Market cap
$2.55B
Enterprise value
$2.49B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.45
Price to sales (P/S)
48.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.37
Earnings
Revenue
$52.6M
EBIT
-$485.5M
EBITDA
-$476.06M
Free cash flow
-$418.08M
Per share
EPS
-$5.36
Free cash flow per share
-$4.38
Book value per share
$10.78
Revenue per share
$0.55
TBVPS
$13.19
Balance sheet
Total assets
$1.26B
Total liabilities
$223.45M
Debt
$110.86M
Equity
$1.04B
Working capital
$786.13M
Liquidity
Debt to equity
0.11
Current ratio
9.03
Quick ratio
8.45
Net debt/EBITDA
0.13
Margins
EBITDA margin
-905%
Gross margin
100%
Net margin
-922.9%
Operating margin
-983.5%
Efficiency
Return on assets
-37.9%
Return on equity
-45.9%
Return on invested capital
-43.6%
Return on capital employed
-41.8%
Return on sales
-922.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
3.36%
1 week
1.42%
1 month
10.25%
1 year
-36.04%
YTD
-13.22%
QTD
18.23%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$52.6M
Gross profit
$52.6M
Operating income
-$517.34M
Net income
-$485.5M
Gross margin
100%
Net margin
-922.9%
The gross profit has grown by 45% from the previous quarter
Intellia Therapeutics's revenue has increased by 45% QoQ
Intellia Therapeutics's operating margin has increased by 31% QoQ but it has decreased by 23% YoY
The company's net margin rose by 30% QoQ but it fell by 15% YoY

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
2.45
P/S
48.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
47.37
The stock's P/B is 55% below its 5-year quarterly average of 5.3 and 15% below its last 4 quarters average of 2.8
Intellia Therapeutics's equity has decreased by 13% YoY
The price to sales (P/S) is 51% lower than the 5-year quarterly average of 94.9 and 25% lower than the last 4 quarters average of 61.6
Intellia Therapeutics's revenue has increased by 45% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
The ROS has grown by 30% from the previous quarter but it has contracted by 15% YoY
The ROA has contracted by 13% YoY and by 4.1% from the previous quarter
Intellia Therapeutics's ROE has decreased by 10% YoY and by 4.6% from the previous quarter

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has decreased by 11% QoQ
The total assets has contracted by 11% YoY and by 3.2% from the previous quarter
The company's debt is 89% lower than its equity
Intellia Therapeutics's equity has decreased by 13% YoY
The company's debt fell by 12% YoY and by 3.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.